NASDAQ:ORTX Orchard Therapeutics (ORTX) Stock Price, News & Analysis → Three basic steps to building the Ultimate Dividend Portfolio. (From DTI) (Ad) Free ORTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.70▼$16.7050-Day Range$16.40▼$16.7052-Week Range$4.24▼$16.72VolumeN/AAverage Volume157,287 shsMarket Capitalization$380.09 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Orchard Therapeutics alerts: Email Address Orchard Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside49.7% Upside$25.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.25) to ($4.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.47 out of 5 starsMedical Sector872nd out of 915 stocksBiotechnology Industry36th out of 43 stocks 3.2 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOrchard Therapeutics has received no research coverage in the past 90 days.Read more about Orchard Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ORTX. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 18 news articles for Orchard Therapeutics this week, compared to 9 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.90% of the stock of Orchard Therapeutics is held by institutions.Read more about Orchard Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($5.25) to ($4.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIThree basic steps to building the Ultimate Dividend Portfolio.There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.Click here to get them (for Free). About Orchard Therapeutics Stock (NASDAQ:ORTX)Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..Read More Ad DTIThree basic steps to building the Ultimate Dividend Portfolio.There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.Click here to get them (for Free). ORTX Stock News HeadlinesMay 24 at 3:15 AM | msn.comUltimatum date set for Orchard Mesa PoolMay 23 at 10:15 PM | msn.comWoman dies in Orchard Mesa murder-suicideMay 23 at 5:15 PM | msn.comMeghan Markle reduced to tears over ‘unfair criticism’ of American Riviera Orchard, royal expert claimsMay 23 at 12:14 PM | finance.yahoo.comPathology & Cytology Laboratories Partners with Orchard Software to Provide Superior Pathology ServicesMay 23 at 12:53 AM | msn.comMeghan Markle ‘in tears’ over American Riviera Orchard criticismMay 22 at 7:52 PM | msn.comMeghan Markle 'Was in Tears' When Her New Lifestyle Brand American Riviera Orchard 'Was Widely Mocked'May 22 at 7:52 PM | msn.comOld Orchard businesses gear up for busy summer seasonMay 22 at 2:51 PM | msn.comMeghan Markle upset over ‘unfair criticism’ of American Riviera Orchard, royal expert claimsMay 22 at 9:51 AM | msn.comBaseball is returning to The Ballpark in Old OrchardMay 21 at 2:54 PM | mirror.co.ukMeghan Markle 'in tears' over 'unfair criticism' of American Riviera OrchardMay 21 at 9:54 AM | msn.comION Orchard leads charge in sustainable takeaway practicesMay 20, 2024 | msn.comInaugural Port Orchard Mosquito Fleet Fest adds a May event on Bay StreetMay 19, 2024 | msn.comION Orchard dives into gamification amidst experiential retail demandMay 19, 2024 | msn.comMan fatally shot Sunday morning in Plum Orchard area, NOPD saysMay 18, 2024 | mirror.co.ukMeghan Markle set to embark on huge PR campaign to promote American Riviera OrchardMay 18, 2024 | msn.comOld Orchard Beach Pier opens for the seasonMay 17, 2024 | msn.comOrchard Mesa Baptist Church holds RV raffleMay 17, 2024 | bizjournals.comOrchard Park home sells for $1.1 millionMay 17, 2024 | msn.comOpening date set for New York Beer Project's Orchard Park locationMay 16, 2024 | msn.comZara Opens New, Expanded Flagship Store At Westfield Old Orchard MallMay 16, 2024 | msn.comMassive Zara opens inside newly renovated Lord & Taylor building at Westfield Old OrchardMay 16, 2024 | msn.comLuxury hotel The Singapore Edition just officially launched – and looks poised to rise above competitors along Orchard Road: we attended the buzzy opening party with Donnie ...May 16, 2024 | yahoo.comNew York Beer Project Beer Lodge in Orchard Park official grand opening set for June 14May 15, 2024 | msn.comReport: Bills set for Week 11 rematch with Chiefs in Orchard ParkMay 14, 2024 | msn.comVehicle causes damage to headstones at Indian Orchard cemeterySee More Headlines Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today5/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$34.00 Low Stock Price Target$16.00 Potential Upside/Downside+49.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,660,000.00 Net Margins-333.90% Pretax Margin-334.54% Return on Equity-74.94% Return on Assets-33.51% Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio2.98 Sales & Book Value Annual Sales$22.66 million Price / Sales16.77 Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book2.16Miscellaneous Outstanding Shares22,760,000Free Float22,099,000Market Cap$380.09 million OptionableOptionable Beta0.55 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Hubert Baburaj Gaspar M.D. (Age 61)Ph.D., CEO, Member of Scientific Advisory Board & Executive Director Comp: $901.42kMr. Frank Edward Thomas (Age 55)President & COO Comp: $763.95kDr. Nicoletta Loggia Ph.D.R.Ph., Chief Technical OfficerDr. Fulvio Mavilio Ph.D.Chief Scientific OfficerMs. Renee T. LeckHead of Investor RelationsBenjamin NavonDirector of Corporate CommunicationsMr. John CerioChief Human Resource OfficerMr. Robin KenselaarSenior VP & GM of EMEA Commercial OperationsMr. Braden ParkerChief Commercial OfficerDr. Leslie Meltzer Ph.D.Chief Medical OfficerMore ExecutivesKey CompetitorsShattuck LabsNASDAQ:STTKSolid BiosciencesNASDAQ:SLDBImmutepNASDAQ:IMMPCorbus PharmaceuticalsNASDAQ:CRBPCelcuityNASDAQ:CELCView All Competitors ORTX Stock Analysis - Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View ORTX analyst ratings or view top-rated stocks. What is Orchard Therapeutics' stock price target for 2024? 3 brokerages have issued 12 month target prices for Orchard Therapeutics' stock. Their ORTX share price targets range from $16.00 to $34.00. On average, they predict the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) issued its earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%. When did Orchard Therapeutics' stock split? Shares of Orchard Therapeutics reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? Orchard Therapeutics (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:ORTX) was last updated on 5/24/2024 by MarketBeat.com Staff From Our PartnersBiden replacement revealed?Paradigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaUrgent Nvidia WarningAltimetryGold Set to EXPLODE!Gold Safe Exchange**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis could mean the end of the U.S dollar…Colonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.